公开(公告)号：EP4430192A2

公开(公告)日：2024-09-18

申请号：EP22893655.5

申请日：2022-11-11

Applicant: The Regents of the University of California

Inventor： ORTIZ URDA, Susana ,  FEICHTENSCHLAGER, Valentin ,  VUJIC, Igor ,  SANLORENZO, Martina ,  CHEN, Emily ,  COPPE, Jean-Philippe

IPC: C12N15/113 ,  A61K31/7115 ,  A61K31/7125 ,  A61K48/00 ,  A61P35/00 ,  G01N33/574

CPC classification number: C12N2310/11320130101 ,  C12N15/1135 ,  C12N2310/1420130101 ,  C12N2310/34120130101 ,  A61P35/00 ,  A61P17/00 ,  A61K45/06 ,  A61K31/519 ,  A61K31/506 ,  A61K31/55 ,  A61K31/4439 ,  A61K31/357 ,  A61K31/713

公开(公告)号：EP4412708A1

公开(公告)日：2024-08-14

申请号：EP22879454.1

申请日：2022-10-05

Applicant: The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone

Inventor： CONKLIN, Bruce ,  NEVIN, Zachary ,  SUN, Mengyuan ,  MATIA, Madeline ,  WATRY, Hannah

IPC: A61P25/28 ,  C12N9/22 ,  C12N15/90 ,  A61K38/46 ,  C12Q1/44

CPC classification number: A61P25/28 ,  C12N9/22 ,  C07K14/4702 ,  C12N2320/3420130101 ,  C12N2310/2020170501 ,  C12N15/1135 ,  C12N15/907

公开(公告)号：EP3527229B1

公开(公告)日：2024-07-03

申请号：EP17862277.5

申请日：2017-10-13

IPC: C12N15/113 ,  A61K31/712 ,  A61K9/127

CPC classification number: A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K47/10 ,  A61K47/24 ,  A61K47/26 ,  A61K48/00 ,  A61P35/00 ,  B82Y5/00 ,  C12N2310/1120130101 ,  C12N2310/32120130101 ,  C12N2310/31520130101 ,  C12N15/1135

公开(公告)号：EP4387674A1

公开(公告)日：2024-06-26

申请号：EP22777867.7

申请日：2022-08-19

Applicant: Northeastern University

Inventor： ZHANG, Ke ,  WANG, Dali

IPC: A61K47/60 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K47/60 ,  A61P35/00 ,  C12N15/1135 ,  C12N2310/1120130101 ,  C12N2310/351520130101 ,  C12N2310/323120130101 ,  C12N2310/31520130101 ,  C12N2310/351720130101

公开(公告)号：EP2513334B1

公开(公告)日：2018-11-14

申请号：EP10838037.9

申请日：2010-06-25

Applicant: Dicerna Pharmaceuticals, Inc.

Inventor： BROWN, Bob, Dale

IPC: A61K31/713 ,  C12N15/113

CPC classification number: C12N15/1135 ,  A61K31/713 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/342 ,  C12N2310/344 ,  C12N2310/533 ,  C12N2320/52 ,  C12N2310/3531 ,  C12N2310/3521

Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.

公开(公告)号：EP3371599A1

公开(公告)日：2018-09-12

申请号：EP16790349.1

申请日：2016-11-02

Applicant: Johann Wolfgang Goethe-Universität Frankfurt am Main

Inventor： KEPPLER, Oliver Till ,  CINATL, Jindrich ,  SCHNEIDER, Constanze ,  BALDAUF, Hanna-Mari ,  SCHWARZ, Sarah-Marie ,  SERVE, Hubert ,  OELLERICH, Thomas ,  GEISSLINGER, Gerd ,  HORNUNG, Veit

IPC: G01N33/574

CPC classification number: G01N33/57488 ,  A61K35/76 ,  A61K35/763 ,  A61P35/00 ,  C12N15/1135 ,  C12N2310/141 ,  C12N2320/31 ,  C12N2710/24132 ,  G01N33/57426 ,  G01N2333/4703 ,  G01N2333/916 ,  G01N2800/52

Abstract: The present invention pertains to novel treatments for cancer diseases. Treatment of cancers with nucleoside analogs (NA), which specifically inhibit rapidly dividing cells, may face preexisting NA resistance or development of resistant cancer cells resulting in poor clinical prognosis. Treatment of cancers with oncolytic herpes simplex viruses (HSV) may face preexisting resistance or development of resistant cancer cells resulting in poor clinical prognosis. The invention overcomes chemotherapy resistance or resistance to oncolytic HSV by providing methods for detecting the resistance in a cancer disease based on the expression of SAM domain and HD domain-containing protein 1 (SAMHD1) in cancer cells. Furthermore provided are treatment options addressing the chemotherapy resistance such as a combination of a SAMHD1 inhibitor with a NA. Moreover, provided are treatment options addressing the resistance to oncolytic HSV such as a combination of a SAMHD1 inhibitor or depletion of SAMHD1 with an oncolytic HSV. The invention provides new medicines and companion diagnostics supporting clinical treatment decisions.

公开(公告)号：EP3347469A2

公开(公告)日：2018-07-18

申请号：EP16845193.8

申请日：2016-09-09

Applicant: Youhealth Biotech, Limited ,  The Regents of the University of California

Inventor： ZHENG, Lianghong ,  ZHU, Jie ,  ZHAO, Ling ,  AI, Michael ,  LI, Oulan ,  ZHANG, Kang

IPC: C12N15/11 ,  C12N15/90 ,  C12N15/87 ,  C12N15/113 ,  A61K48/00 ,  A61P27/06

CPC classification number: A61K38/465 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/127 ,  A61K48/00 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531

Abstract: Disclosed herein are methods and pharmaceutical compositions for the treatment of glaucoma by interfering with expression of genes, such as p16, in cells of the eye. These methods and compositions employ nucleic acid based therapies.

公开(公告)号：EP3345920A1

公开(公告)日：2018-07-11

申请号：EP17209384.1

申请日：2010-10-26

Applicant: Externautics S.p.A.

Inventor： GRIFANTINI, Renata ,  PILERI, Piero ,  CAMPAGNOLI, Susanna ,  GRANDI, Alberto ,  PARRI, Matteo ,  PIERLEONI, Andrea ,  NOGAROTTO, Renzo

IPC: C07K14/47 ,  G01N33/50 ,  G01N33/574

CPC classification number: G01N33/57415 ,  C07K14/4748 ,  C07K16/3015 ,  C07K16/44 ,  C12N15/1135 ,  C12N2310/111 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5011

Abstract: Newly identified proteins as markers for the detection of breast tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.

公开(公告)号：EP3259346A4

公开(公告)日：2018-07-11

申请号：EP16753173

申请日：2016-02-19

Applicant: BAYLOR COLLEGE MEDICINE

Inventor： PATEL VIVEKKUMAR B ,  WANG HONGRAN ,  SINGH VIVEK P ,  REINEKE ERIN LYNN ,  MATHISON MEGUMI ,  COONEY AUSTIN J ,  ROSENGART TODD

IPC: C12N5/071 ,  A61K9/00 ,  A61K31/47 ,  A61K31/713 ,  A61K38/17 ,  A61K48/00 ,  C07K14/47 ,  C07K14/82 ,  C12N5/00 ,  C12N5/077 ,  C12N15/00 ,  C12N15/113 ,  C12N15/86

CPC classification number: C12N15/113 ,  A61K9/0019 ,  A61K31/47 ,  A61K31/713 ,  A61K38/1709 ,  A61K48/0058 ,  C07K14/4702 ,  C07K14/4746 ,  C07K14/82 ,  C12N5/0657 ,  C12N15/1135 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2501/60 ,  C12N2710/10043 ,  C12N2740/15043

Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.

公开(公告)号：EP3250037A4

公开(公告)日：2018-06-20

申请号：EP16738036

申请日：2016-01-18

Applicant: UNIV TEXAS

Inventor： DOIRON BRUNO

IPC: A01N63/00 ,  A01K67/00 ,  C07H21/04 ,  C12N15/00 ,  G01N33/00

CPC classification number: A01K67/0275 ,  A01K2217/056 ,  A01K2217/058 ,  A01K2227/105 ,  A01K2267/0331 ,  C07K14/82 ,  C12N15/1135 ,  C12N2320/31 ,  C12N2740/16043 ,  C12N2310/14 ,  C12N2310/531

Abstract: Certain embodiments are directed kits comprising components for producing a mammalian cancer model. In certain aspects the components are expression vectors. In certain embodiments one or more expression vector is engineered to express a KrasG12D polypeptide, a p53 transcriptional suppressor, SMAD4 transcriptional suppressor, p16/CDKN2 A transcriptional suppressor. In certain aspects the transcriptional suppressor is a short hairpin RNA (shRNA) or other nucleic acid used for RNA interference.